Clinical Trial Update: CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

This clinical trial update reports on a Phase 1 study of CPI-613 (devimistat) in patients with relapsed or refractory small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CPI-613 (devimistat)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Recurrent Small Cell Lung Cancer | Phase 1 | Status: COMPLETED